Dynavax Technologies (DVAX), a biopharmaceutical company, said it has regained full rights to DV1179, an investigational bifunctional inhibitor of toll-like receptors, following the expiration of a research and development collaboration and license agreement with GlaxoSmithKline (GSK). The company will now have global rights to continue the development of DV1179 and other TLR 7/9 inhibitors for all indications.

DVAX previously conducted a Phase 1b/2a study of safety and pharmacodynamics in patients with active systemic lupus erythematosus. The study did not meet the pharmacodynamic endpoints related to reduction in interferon alpha-regulated genes.

The company reported it is looking at opportunities for further development of the inhibitor and has seen promising data for its use in conditions including autoimmune pancreatitis and nonalcoholic steatohepatitis and autoimmune diseases. Shares of DVAX were inactive in early pre-market trading after closing Wednesday at $15.10, within a 52-week range of $12.50 to $21.40. American depositary shares of GSK were down 0.2% at $46.44 in recent pre-market trading, within a 52-week range of $41.91 to $56.73.